Gurutz L.
- Country
- Spain
- Department
- Neurology
Research Overview
- An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease
- Evaluation of Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients with Mild to Moderate Parkinson's Disease and Multiple System Atrophy
- Evaluation of Remternetug (LY3372993) Versus Placebo in Early Alzheimer's Disease Patients at Risk for Cognitive and Functional Decline
Data & Insights
Has run more than one trial at 43 of 171 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in conducting clinical research on neurodegenerative disorders, with a primary focus on movement disorders and cognitive impairment conditions.
- Early-stage Parkinson's Disease investigations
- Multiple System Atrophy research
- Early Alzheimer's Disease studies
The research explores novel therapeutic approaches for managing these progressive neurological conditions.
Movement Disorders
Expertise in evaluating treatments for various movement disorders, particularly focusing on motor symptom management and disease progression.
- Dyskinesia in cerebral palsy
- Motor progression in Parkinson's Disease
- Novel therapeutic compounds for movement control
Research encompasses both symptomatic treatments and disease-modifying approaches.
Therapeutic Innovation
Active involvement in testing innovative therapeutic approaches including antibody treatments, vaccines, and novel compounds.
- Immunotherapy investigations
- Disease-modifying treatments
- Long-term safety evaluations
Focus on developing new treatment options for neurological conditions with significant unmet medical needs.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.